542 related articles for article (PubMed ID: 15345592)
1. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
[TBL] [Abstract][Full Text] [Related]
2. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
3. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
4. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
Iqbal Z; Aleem A; Iqbal M; Naqvi MI; Gill A; Taj AS; Qayyum A; ur-Rehman N; Khalid AM; Shah IH; Khalid M; Haq R; Khan M; Baig SM; Jamil A; Abbas MN; Absar M; Mahmood A; Rasool M; Akhtar T
PLoS One; 2013; 8(2):e55717. PubMed ID: 23409026
[TBL] [Abstract][Full Text] [Related]
5. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Press RD; Love Z; Tronnes AA; Yang R; Tran T; Mongoue-Tchokote S; Mori M; Mauro MJ; Deininger MW; Druker BJ
Blood; 2006 Jun; 107(11):4250-6. PubMed ID: 16467199
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
Sherbenou DW; Wong MJ; Humayun A; McGreevey LS; Harrell P; Yang R; Mauro M; Heinrich MC; Press RD; Druker BJ; Deininger MW
Leukemia; 2007 Mar; 21(3):489-93. PubMed ID: 17252009
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
9. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
10. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
11. Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P; Mohanty S; Kochupillai V; Kumar L
Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
[TBL] [Abstract][Full Text] [Related]
12. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
13. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
Poláková KM; Polívková V; Rulcová J; Klamová H; Jurcek T; Dvoráková D; Zácková D; Pospísil Z; Mayer J; Moravcová J
Exp Hematol; 2010 Jan; 38(1):20-6. PubMed ID: 19837125
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Bashir Q; De Lima MJ; McMannis JD; Garcia-Manero G; Shpall E; Kantarjian H; Cortes JE; O'Brien SM; Jones D; Qazilbash M; Wei W; Giralt SA; Champlin RE; Hosing C
Leuk Lymphoma; 2010 Aug; 51(8):1478-84. PubMed ID: 20658954
[TBL] [Abstract][Full Text] [Related]
15. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Branford S; Rudzki Z; Walsh S; Parkinson I; Grigg A; Szer J; Taylor K; Herrmann R; Seymour JF; Arthur C; Joske D; Lynch K; Hughes T
Blood; 2003 Jul; 102(1):276-83. PubMed ID: 12623848
[TBL] [Abstract][Full Text] [Related]
16. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Branford S; Rudzki Z; Parkinson I; Grigg A; Taylor K; Seymour JF; Durrant S; Browett P; Schwarer AP; Arthur C; Catalano J; Leahy MF; Filshie R; Bradstock K; Herrmann R; Joske D; Lynch K; Hughes T
Blood; 2004 Nov; 104(9):2926-32. PubMed ID: 15256429
[TBL] [Abstract][Full Text] [Related]
17. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
18. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
Gruber FX; Lundán T; Goll R; Silye A; Mikkola I; Rekvig OP; Knuutila S; Remes K; Gedde-Dahl T; Porkka K; Hjorth-Hansen H
Med Oncol; 2012 Mar; 29(1):219-26. PubMed ID: 21221851
[TBL] [Abstract][Full Text] [Related]
20. Resistance to imatinib: mechanisms and management.
Deininger M
J Natl Compr Canc Netw; 2005 Nov; 3(6):757-68. PubMed ID: 16316612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
